Loading
Ivonescimab / Risvutatug rezetecan / Neoplasms, Lung · Phase 1/2 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registry entry for a Phase 1/2 study of risvutatug rezetecan combined with ivonescimab in adults with advanced solid tumors. The trial is not yet recruiting and no results have been posted in the registry. The study is designed to characterize safety, tolerability, pharmacokinetics, and preliminary efficacy (Phase 2 objective response rate) of this novel combination.
Phase 1/2, Interventional, Sequential, Open label, Treatment purpose. Neoplasms, Lung; age from 18 Years. Intervention: Phase 1: Dose escalation; Phase 2: Dose expansion. n = 184. 1 site: Japan.
This is a clinical trial registry entry for a Phase 1/2 study of risvutatug rezetecan combined with ivonescimab in adults with advanced solid tumors. The trial is not yet recruiting and no results have been posted in the registry. The study is designed to characterize safety, tolerability, pharmacokinetics, and preliminary efficacy (Phase 2 objective response rate) of this novel combination.
Efficacy outcome (cORR in Phase 2) is a secondary objective; primary focus is safety and tolerability.
This registration describes a planned early-phase trial with no yet-reported results. Clinicians and researchers should monitor the trial registry for updated recruitment status and eventual results posting. The combination of a topoisomerase-1 inhibitor (risvutatug rezetecan) with an anti-VEGF/Ang2 bispecific antibody (ivonescimab) is investigational and not yet validated in this setting.
This is a Phase 1/2 clinical trial registration with no posted results; it describes a planned early-phase study of a novel combination therapy in advanced solid tumors, designed primarily to establish safety and tolerability.
As stated by the source record.
Quoted from the source exactly as published.
This registration describes a planned early-phase trial with no yet-reported results. Clinicians and researchers should monitor the trial registry for updated recruitment status and eventual results posting. The combination of a topoisomerase-1 inhibitor (risvutatug rezetecan) with an anti-VEGF/Ang2 bispecific antibody (ivonescimab) is investigational and not yet validated in this setting.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07602855). This is a study registration, not published results. Lead sponsor: GlaxoSmithKline. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 184 participants (ESTIMATED). Conditions: Neoplasms, Lung. Interventions: BIOLOGICAL: Risvutatug rezetecan; BIOLOGICAL: Ivonescimab. Primary outcome measures: Phase 1 and Phase 2 Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and Adverse events of special interest (AESIs) , Up to approximately 143 weeks; Phase 1 and Phase 2: Number of participants with AEs leading to dose modifications including study intervention discontinuation , Up to approximately 130 weeks; Phase 2: Number of participants with AEs leading to dose modifications or study intervention discontinuation , Up to approximately 130 weeks; Phase 1 and Phase 2: Number of participants with changes in safety parameters , Up to approximately 143 weeks; Phase 1: Number of participants with Dose Limiting Toxicities (DLT) , Up to 21 days; Phase 1 and Phase 2: Number of participants with a change from baseline in vital signs , Baseline (Day -1) and up to approximately 143 weeks; Phase 1 and Phase 2: Number of participants with a change from baseline in body weight , Baseline (Day -1) and up to approximately 143 weeks; Phase 1 and Phase 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis) , Baseline (Day -1) and up to approximately 143 weeks; Phase 1 and Phase 2: Number of participants with a change from baseline in cardiac function [Electrocardiogram (ECG) and Echocardiogram (ECHO)] , Baseline (Day -1) and up to approximately 143 weeks; Phase 1 and Phase 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status , Baseline (Day -1) and up to approximately 143 weeks; Phase 2:Confirmed Objective Response Rate (cORR) , Up to approximately 143 weeks. Brief summary: This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced solid cancers. The study aims to determine: * What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? * How does the body handle the drug(s)? * What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.